These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30166233)

  • 1. Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept.
    Barakat A; Rufin V; Tran THC
    J Fr Ophtalmol; 2018 Sep; 41(7):603-610. PubMed ID: 30166233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Real life visual and anatomic outcomes of aflibercept treatment for treatment-naive patients with exudative age-related macular degeneration].
    Duval MV; Rougier MB; Delyfer MN; Combillet F; Korobelnik JF
    J Fr Ophtalmol; 2017 Apr; 40(4):270-278. PubMed ID: 28341388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
    Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
    Zinkernagel MS; Wolf S; Ebneter A
    Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration.
    Ohnaka M; Nagai Y; Sho K; Miki K; Kimura M; Chihara T; Takahashi K
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):657-664. PubMed ID: 27743159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
    Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
    Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
    J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
    Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
    Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
    Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
    Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study.
    Veritti D; Sarao V; Parravano M; Arias L; Varano M; Lanzetta P
    Eur J Ophthalmol; 2017 Jan; 27(1):74-79. PubMed ID: 27791249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
    Muftuoglu IK; Arcinue CA; Tsai FF; Alam M; Gaber R; Camacho N; You Q; Freeman WR
    Am J Ophthalmol; 2016 Jul; 167():1-9. PubMed ID: 27049000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the efficacy of aflibercept's in the treatment of neovascular age-related macular degeneration in treatment-naive and switched patients. Report of 86 cases].
    Maringe E; Letesson E; Duncombe A; Muraine M; Genevois O
    J Fr Ophtalmol; 2016 Mar; 39(3):255-60. PubMed ID: 26995074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration.
    Talks JS; Lotery AJ; Ghanchi F; Sivaprasad S; Johnston RL; Patel N; McKibbin M; Bailey C; Mahmood S;
    Ophthalmology; 2016 Feb; 123(2):337-343. PubMed ID: 26578446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial.
    DeCroos FC; Reed D; Adam MK; Salz D; Gupta OP; Ho AC; Regillo CD
    Am J Ophthalmol; 2017 Aug; 180():142-150. PubMed ID: 28624325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Visual and anatomical outcomes of three intravitreal aflibercept injections in eyes with neovascular form of age-related macular degeneration].
    Kałuiny JJ; Majer A; Jaworowska-Cieślińska I
    Klin Oczna; 2015; 117(1):9-13. PubMed ID: 26349151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Nakamura K; Akiyama H
    Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.